Zenas BioPharma, Inc.
NASDAQZenas BioPharma enters the week with an unusual convergence: the CEO has spent roughly $2.1 million buying stock in the open market since March, activists hold Schedule 13D filings on the register, and yet short interest remains pinned near 22% of the free float — a setup where conviction on both sides is unusually high. The insider picture is the most striking angle. CEO Leon…
Snapshot as of 27 Sept 2026
Zenas BioPharma enters the week with an unusual convergence: the CEO has spent roughly $2.1 million buying stock in the open market since March, activists hold Schedule 13D filings on the register, and yet short…
Zenas BioPharma heads into its May 15 results with one of the most aggressive short-interest builds in recent memory — and a CEO who has been buying into the decline with his own cash. Short sellers have dramatically…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZBIO — free to start on ORTEX.
Sign up for free →Open ZBIO on ORTEX